Skip to content
Peptigraph home

Is ARA-290 Legal? FDA, Compounding and WADA Status

ARA-290's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.

Medical review pendingEPO-derived peptideUpdated
FDA status
Not approved
research chemical
PCAC vote
Not reviewed
not on the Jul 2026 PCAC agenda
WADA
Unclear
Not named on the 2026 list
Not legal adviceStatus reflects public FDA and WADA records on the date shown. Rules differ by country and state.

Current status

Not FDA approved · research chemical

No. ARA-290 is not FDA approved for any use.

ARA-290: regulatory status by country
CountryStatusSource
United StatesNo approved product foundNo FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "ARA-290" returned no matches on 2 Oct 2026.api.fda.govchecked 2 Oct 2026

Timeline

No FDA, advisory-committee or WADA action specific to ARA-290 found in our records (checked 2 Oct 2026).
Every peptide on the FDA tracker

Compounding and research-use sellers

  • Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
  • The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
  • "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.

FDA compounding record: Cibinetide (ARA-290) is listed in FDA's 503A category 3 (nominated without adequate support). · fda.gov, checked 2 Oct 2026

Sport and drug testing

WADA status unclear

ARA-290 is not named in the list text. S2.1.5 prohibits innate repair receptor agonists (examples given are EPO derivatives) and ARA-290 is described in the literature as acting on that receptor, but the list does not name it, so we mark class membership as unclear.

Outside the US

Rules differ by country. What each regulator's own records show, with the date we checked:

ARA-290: regulatory status by country
CountryStatusSource
United KingdomNo approved product foundNo approved product found in an emc (UK SmPC compendium) search for "ARA-290" on 2 Oct 2026.medicines.org.ukchecked 2 Oct 2026
CanadaNo approved product foundNo product found in a Health Canada Drug Product Database search for ingredient "ARA-290" on 2 Oct 2026.health-products.canada.cachecked 2 Oct 2026
AustraliaNo approved product foundNo approved product found in an ARTG search for "cibinetide" on 2 Oct 2026.tga.gov.auchecked 2 Oct 2026
European UnionNo centrally authorised EU medicine foundEMA medicines list, searched 2 Oct 2026ema.europa.euchecked 2 Oct 2026

What regulator searches returned for ARA-290

Drugs@FDA returned no match for ARA-290 as an active ingredient.[2]

The UK electronic Medicines Compendium returned no result for ARA-290.[4]

Health Canada's Drug Product Database returned no active-ingredient record for ARA-290.[5]

Australia's ARTG register has no entry under the INN cibinetide, the name used for ARA-290 in some papers.[6]

Compounding list and sport

FDA lists cibinetide (ARA-290) in its 503A category 3 table of nominated substances.[3]

The WADA list names innate repair receptor agonists in class S2.1.5 with erythropoietin derivatives as examples; ARA-290 is not named there, so its class membership is unclear.[1]

Common questions

Is ARA 290 FDA approved?

No approved product was found: the Drugs@FDA search for ARA-290 returned no matches.[2]

Is ARA-290 legal to buy?

It is not an approved drug. Online sellers label it "for research use only, not for human use"; the FDA sent warning letters to five such sellers on 24 Aug 2026. Whether a pharmacy may compound it depends on its FDA bulk-substance status. Rules differ by country.

Is ARA-290 banned by WADA?

It is unclear. ARA-290 is not named in the list text. S2.1.5 prohibits innate repair receptor agonists (examples given are EPO derivatives) and ARA-290 is described in the literature as acting on that receptor, but the list does not name it, so we mark class membership as unclear.

More on ARA-290

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "ARA-290" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3US compounding: Cibinetide (ARA-290) is listed in FDA's 503A category 3 (nominated without adequate support).U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  4. 4United Kingdom: No approved product found in an emc (UK SmPC compendium) search for "ARA-290" on 2 Oct 2026.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
  5. 5Canada: No product found in a Health Canada Drug Product Database search for ingredient "ARA-290" on 2 Oct 2026.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
  6. 6Australia: No approved product found in an ARTG search for "cibinetide" on 2 Oct 2026.Therapeutic Goods Administration (Australia) · 2026tga.gov.auAccessed 2 Oct 2026
  7. 7EMA medicines export (centrally authorised medicines) (searched 2 Oct 2026)European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026

Found an error? Report a correction.